2- dimethylamino- N- (1- (4- methoxybenzenesulfonyl)- 2,3- dihydro- 1H- indol- 7- yl)acetamide

structure in first source

Also Known As:

MPT0B169

Networked: 5 relevant articles (1 outcomes, 1 trials/studies)

Relationship Network

Bio-Agent Context: Research Results

Amino Acids, Peptides, and Proteins: 1
- Amino Acids: 30675
  - Glycine: 5151
    - N-substituted Glycines
      - Sarcosine: 281
        2-dimethylamino-N-(1-(4-methoxybenzenesulfonyl)-2,3-dihydro-1H-indol-7-yl)acetamide: 5
Organic Chemicals: 133
- Amides: 2428
  - Sulfonamides: 2809
    - 2-dimethylamino-N-(1-(4-methoxybenzenesulfonyl)-2,3-dihydro-1H-indol-7-yl)acetamide: 5
- Sulfur Compounds: 278
  - Sulfones: 534
    - Sulfonamides: 2809
      - 2-dimethylamino-N-(1-(4-methoxybenzenesulfonyl)-2,3-dihydro-1H-indol-7-yl)acetamide: 5

Experts

1.	Huang, Huei-Mei: 5 articles (01/2018 - 01/2013)
2.	Wong, Shuit-Mun: 3 articles (01/2018 - 01/2016)
3.	Lee, Yueh-Lun: 3 articles (01/2017 - 01/2016)
4.	Liu, Fu-Hwa: 2 articles (01/2017 - 01/2016)
5.	Liou, Jing-Ping: 2 articles (05/2016 - 01/2013)
6.	Liu, Hsinjin Eugene: 2 articles (05/2016 - 01/2013)
7.	Chen, Yen-Chou: 1 article (01/2018)
8.	Juan, Shu-Hui: 1 article (01/2018)
9.	Lee, Chih-Hsin: 1 article (01/2018)
10.	Lin, Yuan-Feng: 1 article (01/2018)

Related Diseases

1.	Glioblastoma (Glioblastoma Multiforme) 01/01/2018 - "In this study, we investigated the effects of MPT0B169 and MPT0B002 on glioblastoma, breast, lung, and colorectal cancer (CRC) cell lines. " 01/01/2018 - "A cell viability analysis showed that MPT0B169 and MPT0B002 were more effective in inhibiting the proliferation of COLO205 and HT29 CRC cells than U87MG and GBM8401 glioblastoma, MCF-7 and MDA-MB-231 breast cancer, and A549 lung cancer cells. "
2.	Lung Neoplasms (Lung Cancer) 01/01/2018 - "A cell viability analysis showed that MPT0B169 and MPT0B002 were more effective in inhibiting the proliferation of COLO205 and HT29 CRC cells than U87MG and GBM8401 glioblastoma, MCF-7 and MDA-MB-231 breast cancer, and A549 lung cancer cells. "
3.	Breast Neoplasms (Breast Cancer) 01/01/2018 - "A cell viability analysis showed that MPT0B169 and MPT0B002 were more effective in inhibiting the proliferation of COLO205 and HT29 CRC cells than U87MG and GBM8401 glioblastoma, MCF-7 and MDA-MB-231 breast cancer, and A549 lung cancer cells. "
4.	Colorectal Neoplasms (Colorectal Cancer) 01/01/2018 - "In this study, we investigated the effects of MPT0B169 and MPT0B002 on glioblastoma, breast, lung, and colorectal cancer (CRC) cell lines. " 01/01/2018 - "MPT0B169 and MPT0B002, New Tubulin Inhibitors, Induce Growth Inhibition, G2/M Cell Cycle Arrest, and Apoptosis in Human Colorectal Cancer Cells."
5.	BCR-ABL Positive Chronic Myelogenous Leukemia (Chronic Myelogenous Leukemia) 01/01/2017 - "Correction: MPT0B169, a New Antitubulin Agent, Inhibits Bcr-Abl Expression and Induces Mitochondrion-Mediated Apoptosis in Nonresistant and Imatinib-Resistant Chronic Myeloid Leukemia Cells." 01/01/2016 - "MPT0B169, a New Antitubulin Agent, Inhibits Bcr-Abl Expression and Induces Mitochondrion-Mediated Apoptosis in Nonresistant and Imatinib-Resistant Chronic Myeloid Leukemia Cells."

Related Drugs and Biologics

1.	(1- methyl- 1H- indol- 5- yl)- (3,4,5- trimethoxy- phenyl)- methanone
2.	Tubulin Modulators
3.	Paclitaxel (Taxol)
4.	Imatinib Mesylate (Gleevec)
5.	Cyclin B1
6.	Annexin A5
7.	CDC2 Protein Kinase (Protein p34cdc2)
8.	Tubulin
9.	Propidium (Propidium Iodide)
10.	acetamide